Corcept Therapeutics Incorporated (CORT)

Market Cap	6.66B
Revenue (ttm)	628.56M
Net Income (ttm)	140.49M
Shares Out	104.78M
EPS (ttm)	1.26
PE Ratio	50.40
Forward PE	32.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,150,818
Open	65.90
Previous Close	65.09
Day's Range	63.19 - 66.48
52-Week Range	20.84 - 75.00
Beta	0.58
Analysts	Strong Buy
Price Target	97.00 (+52.66%)
Earnings Date	Feb 26, 2025

About CORT

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 352
• Stock Exchange: NASDAQ
• Ticker Symbol: CORT
• Website: https://www.corcept.com

Financial Performance

In 2023, Corcept Therapeutics's revenue was $482.38 million, an increase of 20.04% compared to the previous year's $401.86 million. Earnings were $105.50 million, an increase of 4.15%.

Analyst Forecast

According to 4 analysts, the average rating for CORT stock is "Strong Buy." The 12-month stock price forecast is $97.0, which is an increase of 52.66% from the latest price.

Price Target

$97.0

(52.66% upside)

Analyst Consensus: Strong Buy